SGLT-2 inhibitors were associated with an almost 3-fold increased risk for DKA, with molecule-specific analyses suggesting a class effect (Annals of Internal Medicine)
Diabetes News
Tag: DKA
Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors
SGLT2i are an excellent class of drug in the physician’s toolkit for managing type 2 diabetes. However, both clinicians and patients must be aware of the potential for DKA and the need for increased monitoring, both clinically and biochemically, when potential precipitating factors are present. In acutely unwell patients, these medications should be withheld to reduce the risk of DKA (Journal of Clinical Endocrinology & Metabolism)
Analysing the Clinical Features of Pneumomediastinum Associated with Diabetic Ketoacidosis in 79 Cases
Pneumomediastinum associated with DKA is a rare disease, and it has a benign course when an early diagnosis is made and aetiological treatment is administered (Metabolic Syndrome and Obesity: Targets and Therapy )
The incidence, risk factors, and long-term outcomes of acute kidney injury in hospitalized diabetic ketoacidosis patients
Multiple risk factors contribute to the development of AKI in DKA patients. AKI and advanced AKI stage are associated with rapid progressive CKD and long-term mortality in patients with DKA (BMC Nephrology)
Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes and Glycemic Control over Time: The SEARCH for Diabetes in Youth Study
DKA at T1D diagnosis is associated with worsening glycemic control over time, independent of demographic, socioeconomic and treatment‐related factors and baseline fasting C‐peptide (Peditric Dibetes)
Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis
Neither the rate of administration nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children with diabetic ketoacidosis (NEJM)
Are the results from the 2014 UK national survey on the management of diabetic ketoacidosis applicable to individual centres?
The data from the national DKA survey, even though based on a maximum of 5 people per hospital from across the UK are applicable at a hospital level (Diabetes Research and Clinical Practice)
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
DKA and related events occurred at a low frequency in the canagliflozin type 2 diabetes program, with an incidence consistent with limited existing observational data in the general population with type 2 diabetes (Diabetes Care)
Glycosmedia is also available as an App: